Avanir Pharmaceuticals, Inc (AVNR) news stock charts
Avanir Pharmaceuticals, Inc (AVNR) Investment Summary:
This Annual Report on Form 10-K contains forward-looking statements concerning future events and performance of our Company. When used in this report, the words “intend,” “estimate,” “anticipate,” “believe,” “plan,” “goal” and “expect” and similar expressions as they relate to Avanir are included to identify forward-looking statements. These forward-looking statements are based on our current expectations and assumptions and many factors could cause our actual results to differ materially from those indicated in these forward-looking statements. You should review carefully the factors identified in this report under the caption “Risk Factors.” We disclaim any intent to update or announce revisions to any forward-looking statements to reflect actual events or developments. Except as otherwise indicted herein, all dates referred to in this Report represent periods or dates fixed with reference to the calendar year, rather than our fiscal year ending September 30. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2007%2f12%2f21%2f0000936392-07-000967.html#FIS_BUSINESS"www.avanir.com
20 Employees
Founded in 1988
AVANIR PHARMACEUTICALS INC-A (AVNR:NASDAQ)
LAST $2.08 USD
CHANGE TODAY -0.06 -2.80%
VOLUME 494.7K
As of 8:10 PM 03/19/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of AVANIR PHARMACEUTICALS INC-A (AVNR)
|
OPEN
$2.15
|
PREVIOUS CLOSE
$2.14
|
|
|
DAY HIGH
$2.15
|
DAY LOW
$2.05
|
|
|
52 WEEK HIGH
08/11/09 - $4.09
|
52 WEEK LOW
04/1/09 - $0.39
|
|
|
MARKET CAP
173.4M
|
AVERAGE VOLUME 10 D
448.8K
|
|
|
EPS TTM
$-0.27
|
SHARES OUTSTANDING
83.4M
|
|
|
AVNR Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for AVANIR PHARMACEUTICALS INC-A (AVNR)
Avanir Pharmaceuticals expected to Report Q2 2010 Results on May 3, 2010. This event was calculated by Capital IQ (Created on February 12, 2010).
02/12/2010
Avanir Pharmaceuticals expected to Report Q2 2010 Results on May 3, 2010. This event was calculated by Capital IQ (Created on February 12, 2010).
Avanir Pharmaceuticals Reports Unaudited Consolidated Earnings Results for the First Quarter Ended December 31, 2009
02/2/2010
Avanir Pharmaceuticals reported unaudited consolidated earnings results for the first quarter ended December 31, 2009. For the period, the company reported a net loss of $4.8 million, or $0.06 loss per share, compared with a net loss of $5.2 million, or $0.07 loss per share, for the same period in fiscal 2009. Net revenues were $1.5 million, compared with $1.8 million for the same period in fiscal 2009. Cash used in operations was $6.5 million.
Avanir Pharmaceuticals to Report Q1, 2010 Results on February 02, 2010
01/26/2010
Avanir Pharmaceuticals announced that they will report Q1, 2010 results before the start of trading on February 02, 2010.
Avanir Pharmaceuticals, Inc financial resources
AVNR Competitors
| Company | Last | Change |
| Amgen Inc | $60.00 USD | +1.69 |
| Biovail Corp | C$16.11 CAD | +0.09 |
| Chattem Inc | $93.49 USD | 0.00 |
| Forest Laboratories Inc | $31.06 USD | -0.41 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | AVNR | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 44.3x |
|
| Price/Book | 10.8x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 38.0x |
|
|
AVNR |
||
|
AVNR transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent Financial News About Avanir Pharmaceuticals, Inc
AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 First Quarter Conference Call
2010-03-19 07:59:52
Quote: Read article
AVANIR Pharmaceuticals Announces Fiscal 2010 First Quarter Financial Results
2010-03-02 07:37:54
Quote: ALISO VIEJO, Calif.--(BUSINESS WIRE)--AVANIR Pharmaceuticals, Inc.AVNRNews) today reportedunaudited financial results for the three months ended December 31, 2009.For the first quarter of fiscal 2010, AVANIR reported a net loss of $4.8million, or $0.06 loss per share, compared with a net loss of $5.2million, or $0.07 loss per share, for the same period in fiscal 2009.Net revenues for the first quarter of fiscal 2010 were $1.5 million,compared with $1.8 million for the same period in fiscal 2009....Read article
AVANIR to Present at the 12th Annual BIO CEO & Investor Conference
2010-03-02 07:37:53
Quote: Press ReleaseSource: AVANIR Pharmaceuticals, Inc.On Tuesday February 2, 2010, 4:15 pm EST(NASDAQ:- ) today announced thatthe Company will present at the 12 Annual BIO CEO &Investor Conference on Tuesday, February 9 at 9:30 a.m.Eastern time (6:30 a.m. Pacific time) at the Waldorf-Astoria in NewYork. The BIO CEO & Investor Conference is the largest conferencefocused on publicly traded biotechnology companies and providesparticipating companies with the opportunity to present to industryanalysts, i...Read article
AVANIR Pharmaceuticals Announces Issuance of New U.S. Zenvia Patent
2010-03-02 07:37:52
Quote: ALISO VIEJO, Calif.--(BUSINESS WIRE)--AVANIR Pharmaceuticals, Inc.AVNRNewsPharmaceutical Compositions Comprising Dextromethorphan andQuinidine for the Treatment of Neurological Disorders" was issued onFebruary 9, 2010. The new patent will provide AVANIR with patentprotection for low-dose quinidine formulations of Zenvia used to treatpseudobulbar affect (PBA).“We are very pleased the USPTO has issued this patent for our newlow-dose quinidine formulations of Zenvia in the treatment of PBA,â...Read article
AVANIR PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
2010-02-24 03:23:45
Quote: Read article
AVANIR Pharmaceuticals Announces Issuance of New U.S. Zenvia Patent
2010-02-11 04:42:36
Quote: ALISO VIEJO, Calif.--(BUSINESS WIRE)--AVANIR Pharmaceuticals, Inc.AVNRNewsPharmaceutical Compositions Comprising Dextromethorphan andQuinidine for the Treatment of Neurological Disorders" was issued onFebruary 9, 2010. The new patent will provide AVANIR with patentprotection for low-dose quinidine formulations of Zenvia used to treatpseudobulbar affect (PBA).“We are very pleased the USPTO has issued this patent for our newlow-dose quinidine formulations of Zenvia in the treatment of PBA,â...Read article
AVANIR PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
2010-02-03 02:58:55
Quote: Results of Operations and Financial Condition.
On February 2, 2010, AVANIR Pharmaceuticals, Inc. issued a press release
announcing its financial results for the three months ended December 31, 2009
(the "Press Release"). A copy of the Press Release is furnished herewith as
Exhibit 99.1.
The information set forth under Item 2.02 and in Exhibit 99.1 shall not be
deemed "filed" for purposes of Section 18 of the Securities Exchange Act of
1934, nor shall it be deemed incorpora...Read article
AVANIR Pharmaceuticals Announces Fiscal 2010 First Quarter Financial Results
2010-02-03 02:58:55
Quote: ALISO VIEJO, Calif.--(BUSINESS WIRE)--AVANIR Pharmaceuticals, Inc.AVNRNews) today reportedunaudited financial results for the three months ended December 31, 2009.For the first quarter of fiscal 2010, AVANIR reported a net loss of $4.8million, or $0.06 loss per share, compared with a net loss of $5.2million, or $0.07 loss per share, for the same period in fiscal 2009.Net revenues for the first quarter of fiscal 2010 were $1.5 million,compared with $1.8 million for the same period in fiscal 2009....Read article
Q1 2010 AVANIR Pharmaceuticals Earnings Release - Before Market Open
2010-02-03 02:58:55
Quote: Gallagher & Co.AJG0.23After Market CloseAddListenArtioART0.4607:00 am ETAddListenArvinMeritor, Inc.ARM-0.07Before Market OpenAddAtmos Energy CorporationATO0.91After Market CloseAddAutomatic Data ProcessingADP0.58Before Market OpenAddAVANIR PharmaceuticalsAVNR-0.06Before Market OpenAddAxfood ABAXFOF.PKN/A01:30 am ETAddBE AerospaceBEAV0.31Before Market OpenAddListenBP plcBP1.5102:00 am ETAddBRE Properties, Inc.BRE0.53After Market CloseAddC.H. Robinson Worldwide IncCHRW0.564:15 pm ETAdd...Read article
Avanir Pharmaceuticals, Inc. F1Q10 (Qtr End 12/31/09) Earnings Call Transcript
2010-02-03 02:58:54
Quote: Avanir Pharmaceuticals, Inc. (AVNR)
F1Q10 (Qtr End 12/31/09) Earnings Call Transcript
February 2, 2010 11:00 am ET
Executives
Brenna Mullen – IR
Keith Katkin – President and CEO
Christine Ocampo – VP, Finance
Randall Kaye – SVP, Clinical Research and Medical Affairs, Chief Medical Officer
Analysts
Mike King – Merriman Curhan Ford
Carol Werther – Summer Street Research Partners
Jim McCamant – America HealthCare
Mark Mcinerney – Visium Assets...Read article
AVANIR to Present at the 12th Annual BIO CEO & Investor Conference
2010-02-03 02:58:54
Quote: Press ReleaseSource: AVANIR Pharmaceuticals, Inc.On Tuesday February 2, 2010, 4:15 pm EST(NASDAQ:- ) today announced thatthe Company will present at the 12 Annual BIO CEO &Investor Conference on Tuesday, February 9 at 9:30 a.m.Eastern time (6:30 a.m. Pacific time) at the Waldorf-Astoria in NewYork. The BIO CEO & Investor Conference is the largest conferencefocused on publicly traded biotechnology companies and providesparticipating companies with the opportunity to present to industryanalysts, i...Read article
AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 First Quarter Conference Call
2010-01-27 02:55:47
Quote: Read article
AVANIR Pharmaceuticals Presents Zenvia Phase III Results in Amyotrophic Lateral Sclerosis Patient Cohort at the International Symposium on ALS / MND
2009-12-11 01:33:04
Quote: Read article
AVANIR to Present at the Lazard Healthcare Conference
2009-11-30 02:03:42
Quote: A live audio webcast of the presentation will be available by visitingAVANIR's website at AVANIR Pharmaceuticals, Inc. is a biopharmaceutical company focused onacquiring, developing, and commercializing novel therapeutic productsfor the treatment of central nervous system disorders. AVANIR's leadproduct candidate, Zenviaâ„¢, is being developed for the treatment ofpseudobulbar affect (PBA) and has successfully completed a Phase IIItrial for diabetic peripheral neuropathic (DPN) pain. AVANIR h...Read article
AVANIR Pharmaceuticals Invites Investors to Fourth Quarter and Fiscal Year End Conference Call
2009-11-30 02:03:41
Quote: Investors are invited to listen to the live webcast by visiting AVANIR’scorporate website at AVANIR Pharmaceuticals, Inc. is a biopharmaceutical company focused onacquiring, developing, and commercializing novel therapeutic productsfor the treatment of central nervous system disorders. AVANIR's leadproduct candidate, Zenvia™, is being developed for the treatment ofpseudobulbar affect (PBA) and has successfully completed a Phase IIItrial for diabetic peripheral neuropathic (DPN) pain...Read article
AVANIR Pharmaceuticals Announces Fiscal 2009 Fourth Quarter and Full Year Financial Results
2009-11-30 02:03:40
Quote: ALISO VIEJO, Calif.--(BUSINESS WIRE)--AVANIR Pharmaceuticals, Inc.AVNRNews) today reportedunaudited financial results for the three and twelve months endedSeptember 30, 2009.For the fourth quarter of fiscal 2009, AVANIR reported a net loss fromcontinuing operations of $7.0 million, or $0.09 per share, compared witha net loss from continuing operations of $5.2 million, or $0.07 pershare, for the same period in fiscal 2008. Net revenues from continuingoperations for the fourth quarter of fiscal 20...Read article
Q4 2009 AVANIR Pharmaceuticals Earnings Release - Before Market Open
2009-11-30 02:03:40
Quote: Earnings
Announcements for
Tuesday, November 24CompanySymbolTimeConferenceCallAlimentation Couche-Tard Inc.ATD-A.TOTime Not SuppliedAllied HealthcareAHCIBefore Market OpenAmerican Eagle Outfitters IncAEO08:00 am ETListenAmerican Italian Pasta CoAIPCTime Not SuppliedAmerican Woodmark CorporationAMWDTime Not SuppliedAmtech SystemsASYSAfter Market CloseAVANIR PharmaceuticalsAVNRBefore Market OpenBank Of MontrealBMOTime Not SuppliedBarnes & NobleBKSBefore Market OpenListenBlue Coat SystemsBCSIAf...Read article
AVANIR PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events
2009-11-30 02:03:40
Quote: AVANIR PHARMACEUTICALS, INC.Request a Trial to NEW EDGAR Online Pro
Form
8-K for
AVANIR PHARMACEUTICALS, INC.
17-Nov-2009Change in Directors or Principal Officers, Other Events
Privacy PolicyTerms of ServiceCopyright/IP PolicySend FeedbackSEC
Filing data and information provided by EDGAR Online,
Inc.
(1-800-416-6651). All information provided "as is"
for informational purposes
only, not intended for trading purposes or advice.
Neither Yahoo! nor any of
independent providers is liable for any inf...Read article
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
2009-11-30 02:03:39
Quote: Avanir Pharmaceuticals (AVNR)
F4Q09 (Qtr End 09/30/2009) Earnings Call
November 24, 2009 11:00 am ET
Executives
Brenna Mullen - IR
Keith Katkin - President and CEO
Christine Ocampo - VP, Finance
Randy Kaye - SVP, Clinical Research and Medical Affairs and CMO
Analysts
Carol Werther
Robin Davison
Jim McCamant
Mike King
Presentation
Operator
At this time, I would like to welcome everyone to the AVANIR Pharmaceuticals' Fiscal 2009 fourth quarter and year-end conference call. (Operator Instruction...Read article
AVANIR PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
2009-11-30 02:03:39
Quote: Results of Operations and Financial Condition.
On November 24, 2009, AVANIR Pharmaceuticals, Inc. issued a press release
announcing its financial results for the three and twelve months ended
September 30, 2009 (the "Press Release"). A copy of the Press Release is
furnished herewith as Exhibit 99.1.
The information set forth under Item 2.02 and in Exhibit 99.1 shall not be
deemed "filed" for purposes of Section 18 of the Securities Exchange Act of
1934, nor shall it be dee...Read article
Would you like to leave a comment about Avanir Pharmaceuticals, Inc AVNR
Find out what social network information about Avanir Pharmaceuticals, Inc are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Avanir Pharmaceuticals, Inc's Stock there is more great penny stock and market information at Realpennies